NCT05100082

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Special Drug Use Surveillance for Cabometyx Tablets "Hepatocellular Carcinoma"

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 263 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is a survey in Japan of Cabozantinib tablets used to treat Japanese people with a type of liver cancer called hepatocellular carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with hepatocellular carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 12 months.

Conditions

• Hepatocellular Cancer

Interventions

Type	Name	Description
DRUG	Cabozantinib	Cabozantinib tablets

Timeline

• Start date: 2021-11-17
• Primary completion: 2025-11-30
• Completion: 2025-11-30
• First posted: 2021-10-29
• Last updated: 2025-12-30

Locations

1 site across 1 country: Japan